Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 17/20 | 0.50 |
| ▸ | CTSL | P07711 | 5/20 | 0.40 |
| ▸ | CTSB | P07858 | 5/20 | 0.40 |
| ▸ | CTSH | P09668 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL328961 | 1.00 | CTSK (0.50) | CTSKCTSLCTSBCTSHCHRM1 | |
| SCHEMBL4820415 | 0.88 | CTSK (0.60) | CTSKCTSLCTSBCTSH | |
| SCHEMBL4820406 | 0.88 | CTSK (0.60) | CTSKCTSLCTSBCTSH | |
| SCHEMBL56438 | 0.83 | CTSK (0.50) | CTSKCTSLCTSBCTSHTAS1R3 | |
| SCHEMBL1914295 | 0.82 | — | — | |
| SCHEMBL1643969 | 0.82 | — | — | |
| SCHEMBL27181601 | 0.82 | — | — | |
| SCHEMBL13245698 | 0.81 | CTSK (0.49) | CTSKCTSLCTSBCTSHCHRM1 | |
| SCHEMBL1991650 | 0.79 | CTSK (0.60) | CTSKCTSLCTSBCTSH | |
| SCHEMBL13624945 | 0.79 | CTSK (0.47) | CTSKCTSLCTSBCTSHTAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008086053-A1 | HCV INHIBITORS | VIROBAY, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20070099950-A1 | Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain | AGT SCIENCE LIMITED (GB) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099950-A1 | Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain | PER2, CNR2, OPRD1 | CTSK 2839/4885CTSL 3684/4885CTSB 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.